购物车
- 全部删除
- 您的购物车当前为空
Daclizumab (Zenapax)为人源化单抗,能特异性地抑制IL-2R-HA的α亚单位。Daclizumab (Zenapax)能通过与CD25的特异性结合而抑制IL-2和IL-2R-HA的结合。Daclizumab (Zenapax)研究多发性硬化症 。
为众多的药物研发团队赋能,
让新药发现更简单!
Daclizumab (Zenapax)为人源化单抗,能特异性地抑制IL-2R-HA的α亚单位。Daclizumab (Zenapax)能通过与CD25的特异性结合而抑制IL-2和IL-2R-HA的结合。Daclizumab (Zenapax)研究多发性硬化症 。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 997 | 现货 | |
5 mg | ¥ 2,890 | 现货 | |
10 mg | ¥ 4,990 | 现货 | |
25 mg | ¥ 7,790 | 现货 | |
50 mg | ¥ 10,500 | 现货 | |
100 mg | ¥ 14,200 | 现货 |
产品描述 | Daclizumab (Zenapax) is a humanized monoclonal antibody that specifically inhibits the alpha subunit of IL-2R-HA. Daclizumab (Zenapax) can inhibit the binding of IL-2 and IL-2R-HA through specific binding to CD25. Daclizumab (Zenapax) studies multiple sclerosis. |
别名 | 达昔单抗, Zenapax, Ro 24-7375 |
分子量 | 144.12 kDa |
CAS No. | 152923-56-3 |
存储 | store at low temperature | store at -80°C | Shipping with blue ice. |
评论内容